tradingkey.logo
tradingkey.logo
Search

Kezar Life Sciences Inc

KZR
Add to Watchlist
7.290USD
0.0000.00%
Close 07/02, 13:00ETQuotes delayed by 15 min
53.86MMarket Cap
LossP/E TTM

TradingKey Stock Score of Kezar Life Sciences Inc

Currency: USD Updated: 2026-05-08

Key Insights

Kezar Life Sciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kezar Life Sciences Inc's Score

Industry at a Glance

Industry Ranking
142 / 384
Overall Ranking
280 / 4494
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Kezar Life Sciences Inc Highlights

StrengthsRisks
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Undervalued
The company’s latest PE is -0.95, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.52M shares, decreasing 18.35% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 131.28K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
6.000
Target Price
-17.70%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Kezar Life Sciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Kezar Life Sciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Kezar Life Sciences Inc’s performance and outlook.

How do we generate the financial health score of Kezar Life Sciences Inc?

To generate the financial health score of Kezar Life Sciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Kezar Life Sciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Kezar Life Sciences Inc.

How do we generate the company valuation score of Kezar Life Sciences Inc?

To generate the company valuation score of Kezar Life Sciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Kezar Life Sciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Kezar Life Sciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Kezar Life Sciences Inc.

How do we generate the earnings forecast score of Kezar Life Sciences Inc?

To calculate the earnings forecast score of Kezar Life Sciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Kezar Life Sciences Inc’s future.

How do we generate the price momentum score of Kezar Life Sciences Inc?

When generating the price momentum score for Kezar Life Sciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Kezar Life Sciences Inc’s prices. A higher score indicates a more stable short-term price trend for Kezar Life Sciences Inc.

How do we generate the institutional confidence score of Kezar Life Sciences Inc?

To generate the institutional confidence score of Kezar Life Sciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Kezar Life Sciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Kezar Life Sciences Inc.

How do we generate the risk management score of Kezar Life Sciences Inc?

To assess the risk management score of Kezar Life Sciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Kezar Life Sciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Kezar Life Sciences Inc.